CJON BOOK EXCERPT SERIES
From Access Device Guidelines: Recommendations for Nursing Practice and Education (2nd ed., pp. A. Description and types of devices (Martin, 2002) 1. Arterial therapy delivers medication directly into an organ or tumor via the main supply artery, or in the case of metastatic hepatic tumors, through the common hepatic gastroduodenal arteries. 2. Three types of access are used (Martin, 2002 ). a) Short-term percutaneous catheters inserted via the femoral or brachial artery b) Long-term catheters placed during surgery and either used as an external catheter or attached to an implanted port or pump c) Implanted ports for long-term therapy 3. Catheters and ports: Catheters composed of polyethylene, Pebax ® nylon (a nylon derivative) (ATOFINA Chemicals, Philadelphia, PA), or Silastic ® (Dow Corning, Midland, MI) materials with internal diameters ranging from 0.5-1.5 mm and outer diameters ranging from 2.7-9.6 French are used. Catheter openings may be at the end or have a closed end with a side hole (Seki et al., 1999) . Portal bodies are described in Section II-H. 4. Silastic beaded catheter has raised circular rings placed approximately 1 to 2 cm apart. For surgical placement of catheter, sutures are positioned around the catheter and between the beads to secure the catheter in place and prevent it from migrating out of the artery (Martin, 2002) . 5. Arterial catheter gauge has a smaller internal diameter and thicker catheter wall compared to a venous catheter because of slower arterial administration times, higher vascular arterial pressures, plus it acts as a safety measure to reduce blood backflow.
6. Catheters are available with one-way valves to prevent retrograde blood flow. 7. Procedural and overall costs vary. a) Costs for placement: Surgical placement of catheter with direct access to artery, with or without a port, is initially more costly than percutaneous insertion of catheter (Zanon et al., 1998) . However, depending on the number of percutaneous reinsertions of catheter, this procedure may become more expensive than surgical placement. b) Discussion continues on the clinical and economic benefits of arterial therapy versus systemic therapy (Cole, 1996; Haller, 2000; Kemeny & Fata, 2001 ). An initial comparison of costs for hepatic arterial therapy, systemic therapy, and symptom control for colorectal liver metastases revealed hepatic arterial therapy to be the most costly. The cost-effectiveness of hepatic arterial chemoembolization for the treatment of colorectal liver metastases varies considerably according to the anticipated survival benefit (Abramson et al., 2000) . 8. Table 7 lists the advantages and disadvantages of an arterial catheter (long-term and short-term) versus an arterial port for arterial infusions. B. Advantages and disadvantages of arterial therapy 1. Advantages a) Regional perfusion is useful only when the entire tumor is perfused and infusate can be confined to a specific area (Weinstein, 2001 ). Efforts are being made to further restrict systemic circulation of infusate using techniques such as arterial, mechanical, or chemical embolization (Alsowmely & Hodgson, 2002) . b) Only in the case of hepatic perfusion may access be achieved through the hepatic artery, as well as through the portal vein, and consideration is being given to use both accesses for drug delivery to the tumor (Paku, Bodoky, Kupcsulik, & Timar, 1998) . c) Increased exposure of tumor to drug increases tumor response, whereas less systemic circulation and exposure to infusate decreases risk of systemic side effects (Dizon & Kemeny, 2002; Goodman, 2000; Haller, 2000; Kemeny, 2000) . 2. Disadvantages a) Less systemic circulation and exposure to infusate increases the risk for distant metastasis. b) Positive outcomes from arterial therapy, such as improved survival and quality of life, remain under continued investigation (Haller, 2000; Kemeny, 2000 (Habbe et al., 1998) (1) The liver is the focal point of disease, although extrahepatic metastatic disease may be present (Bergsland & Venook, 2000) . 5. Check for sites of organ or regional perfusion for malignant disease with arterial access (see Table 8 ). 6. Consider contraindications for arterial access. a) Acute infection, prolonged fever, and absolute neutrophil count < 1,500 mm Internal iliac or hypogastric arteries Note. Infusates for all regions are continually being tested and updated; these include cytotoxic agents, immunotherapy, and others. Consult a drug or chemotherapy handbook for specific infusates.
Although commonly viewed as a permanent catheter, it may be removed if a specific surgical technique is used (Maruyama, Takamatsu, Nagahama, & Ebuchi, 1999 (Habbe et al., 1998) . c) A newer technique uses a fixedtip catheter, reducing migration (Irie, 2001; Seki et al., 1999) . In the fixed-tip catheter placement, the open end of the catheter is attached to the gastroduodenal artery with microcoils that also discontinue blood flow to this artery and occlude the open end of the catheter. A side hole in this catheter is located in the hepatic artery, which is the desired location for drug administration. d) Catheter may be inserted percutaneously and connected to a subcutaneous (SC) port (Seki et al., 1999) . e) Disadvantages to percutaneous access include the following. (Habbe et al., 1998) . b) Antiembolic stockings are recommended to decrease risk of thrombus (West, 1998 fects follows a similar pattern as if the drug was given systemically; thus assessment depends on the drug given. 3. Infusates used in regional therapy include cytotoxic agents, lymphocytes, and tumor necrosis factor. Any drug can be delivered through an implanted port without concerns about drug-device biocompatibility because of the limited time of contact with the drug and port (Graham & Holohan, 1994) . 4. Administration schedule depends on specific protocol. a) Drugs may be given as a bolus, intermittent, or continuous longterm infusion using either external or implanted pumps. The drug administration may continue for a specified number of cycles or indefinitely until there is response or disease progression (Lorenz & Muller, 2000) . b) Hepatic arterial infusions through a temporary percutaneous catheter often are for four days, then the catheter is pulled. The cycle is frequently repeated for several months (Copur et al., 2001 ).
5. A pump is required for arterial infusions; this may be an implantable pump or an external pump (see Section VII). 6. Arterial access devices are not to be used for other therapies (e.g., total parenteral nutrition, lipid administration). I. Access, flushing, and dressing (see Table  9 ) 1. For proper use of these devices, the nurse should be familiar with the device, its features, patient-and drugrelated considerations, and precautions provided by the manufacturer. • Amount is at least two times the catheter plus add-on set volume • 5,000 units heparin/ml, usually 3-5 ml every day Before and after each drug: 20 ml normal saline (West, 1998) Final flush:
• Amount is 5 ml • 1,000 units heparin/ml or 5,000 units heparin/ml* weekly
EXIT SITE CARE AND DRESSINGS
Perform usual incisional care post-op.
Continue exit site care for external catheters or for port with needle access during continuous infusions.
• Apply sterile, occlusive dressing.
• Change dressing every two days for gauze and at least weekly for transparent semipermeable dressing (Centers for Disease Control and Prevention [CDC], 2002).
• Change port needle every seven days.
• Use alcohol, povidone-iodine, or 2% chlorhexidine-based skin prep (CDC, 2002 ).
• Do not use topical antibiotic ointment or cream on insertion sites; potential to promote fungal infections and antimicrobial resistance (CDC, 2002) .
Gauze wrap occasionally is used to protect the catheter and keep patient from bending or pulling catheter within involved extremity.
* If 1,000 units/ml is used, aspirate heparin solution from catheter before infusion and monitor coagulation values.
through a port: If no blood return or perfusion, radiographic check needs to be obtained to verify catheter placement. f) Interventions for painful needle sticks during port access are described previously (see Section II-B-4 on peripheral IVs). 5. Flushing to maintain patency a) Controversy exists related to the type, amount, and concentration of final flush solutions. b) For information on port flushing, see Table 9 . c) Flushing for external catheters (see Table 9 ) (1) Post-surgery: Usually instilled with 1,000 units of heparin/ml using 2 ml. (b) Flush with heparin solution as ordered by physician to maintain catheter patency (Martin, 2002 
